Jonathan Silverstein Headshot
Report a problem with this profile
[email protected]

Jonathan Silverstein    

General Partner, OrbiMed

Jonathan Silverstein co-heads private equity business at OrbiMed, the world's largest fund fully dedicated to healthcare ($15 billion under management). Silverstein, who joined the firm in 1999, has had 21 exits in his career. Hits of late include Avanir Pharmaceuticals (acquired by Otsuka for $3.5 billion in 2014), Relypsa (IPO 2013), Arteaus Therapeutics (its migraine drug was acquired by Lilly in 2014) Enobia (acquired by Alexion for $1.08 billion), superDimension (acquired by Covidien for $300 million) and Intercept Pharma (IPO 2012). Other exits include Insulet, NxStage and Auxillium Pharmaceuticals. Silverstein also chairs the boards of Intercept, Cerapedics and Audentes. A father of three young children, he gets inspiration from the likes of Steve Jobs as well as cult rap group Insane Clown Posse. His favorite drink is the piƱa colada.


No videos yet.

Related Speakers View all

More like Jonathan